Pregabalin Capsule
Product Images NDC 70518-3345

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-3345). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Pregabalin 150mg 70518 3345 01)

This text is a label for Pregabalin medication manufactured by Novadoz Pharmaceuticals LLC in New Jersey with an NDC code of 70518-3345-01 and a strength of 150mg. The medication comes in a bottle with 90 capsules and should be kept out of the reach of children. The lot number and expiration date are not mentioned. The package insert should be referred to for usage instruction, and the medication should be stored between 20-26°C (63-77°F). It has been repackaged by RemedyRepack Inc in Indiana, PA for Rx only.*

FDA Label Image

Remedy_label (Remedy Label)

Pregabalin is a medication sold with NDC# 70518-3345-00 that is manufactured in 150 mg capsules by Novadoz Pharmaceuticals LLC, Paterson, New Jersey, USA. The lot number and expiration date are not readable in the given text. The packing includes 60 capsules that come with package inserts. The medication is repackaged by RemedyRepack Inc., Indiana, PA. It is advised to store the medication within 20-26°C (63-77°F), with excursions permitted to 15-30°C (59-86°F) [See USP]. Keep out of reach of children.*

FDA Label Image

Equation (Pregabain Gault Equation)

FDA Label Image

Fig-01 (Pregabalin Figure 01)

This text provides the percentage of patients who improved in relation to different dosages of Pregabalin and a placebo. The improvement is measured in pain reduction from a baseline value. The text includes a graph showing the percentage of patients improved at different levels for each dosage of Pregabalin and the placebo.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

The data shows the percentage of patients who improved after taking Pregabalin 100 mg three times a day versus a placebo. The graph displays the percentage of pain improvement from baseline, with the Pregabalin group showing significant improvement compared to the placebo group.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

The text represents a chart showing the percent of improvement in pain for patients using Pregabalin at different dosages and a placebo. The chart shows a range of percent improvement from 0 to 90. There is no other information available to provide a meaningful description.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

The text presents a graph that shows the percentage of patients who improved while taking Pregabalin 200mg three times a day, Pregabalin 100mg three times a day, and Placebo. The percentages are organized according to the percentage of improvement in pain from the baseline, ranging from >10 to >90%.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

This appears to be a chart showing the percentage of patients who experienced improvement in pain based on different dosages of Pregabalin and a placebo. The chart displays percentages ranging from 10% to 100% with the corresponding dosage and treatment displayed next to each percentage. The chart provides information on the effectiveness of different dosages of Pregabalin in treating pain.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

The text is presenting responder rates (%) of different studies (E1, E3) testing various dosages of an unspecified medication. The medication doses tested were 50mg/day, 150mg/day, 300mg/day, and 600mg/day. The responder rates ranged from 9-51% and were statistically significant. No further information or context is available.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

This appears to be a graph or chart with some statistical values indicating significant p-values when comparing different doses. However, without more context or information it is not possible to provide a more accurate description.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

This appears to be a graph depicting the percent of patients who have improved over time in response to different doses of pregabalin versus a placebo. The x-axis indicates the percentage of pain improvement from baseline, while the y-axis lists the different doses of pregabalin and the placebo. Some of the doses include 300 mg, 450 mg, and 600 mg per day. However, without additional context, it is difficult to provide more specific information.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

FDA Label Image

Fig-11 (Pregabalin Figure 11)

The text is a graph representing the percentage of subjects who showed improvement from baseline to week 12 for the drug Pregabalin and Placebo. The horizontal axis represents the percentage range from 0 to 100, and the vertical axis shows the percentage of subjects improved. The graph suggests that Pregabalin had a higher percentage of subjects who improved compared to Placebo.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

This is a graph representing the percentage of subjects who experienced improvement from baseline to week 16 using Pregabalin and Placebo. The top axis represents the percentage of improvement, from 10% to 100%, and the side axis represents the number of subjects.*

FDA Label Image

Str (Pregabalin Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.